NCCI 2026 State of the Line: Workers Comp Profitability Masks a Medical Severity Pivot

From tracking NCCI loss cost filings across 38 states for the past several years, the pattern was consistent: frequency declining, severity contained, rate decreases filed in most jurisdictions, and favorable prior-year development padding calendar year results. That pattern held through 2023. It started cracking in 2024, and the data heading into the 2026 NCCI Annual Issues Symposium in Orlando suggests the medical severity component has changed direction in ways that matter for every workers compensation rate filing in the pipeline.

NCCI's State of the Line report is the most authoritative industry-level loss cost benchmark for workers compensation. The 2025 report (covering calendar year 2024 with preliminary accident year data) showed medical claim severity increasing 6%, tripling from the 2% print in 2023 and exceeding the 5% figure from 2022. Indemnity claim severity rose 6% as well, matching 2022 levels. The headline combined ratio of 86 stayed comfortably profitable, but that number reflects substantial favorable prior-year reserve development that masks the deteriorating current accident year story underneath.

The Aggregate Numbers: Profitable but Thinning

The workers compensation calendar year combined ratio has been the most consistent profitability story in P&C insurance. The line printed 84 in 2022, climbed slightly to 86 in 2023, and held at 86 in 2024, making it the lowest combined ratio among major P&C lines in each of those years. NCCI's State of the Line described eight consecutive years with the combined ratio below 90 as of the 2025 report, and the 2024 result extended that streak to nine.

The calendar year figure, however, is the wrong number for pricing work. Accident year 2024 printed at 99, a 13-point gap from the calendar year result. That gap is entirely prior-year favorable development flowing through from the AY 2010 through 2020 cohort. Industry reserve redundancy, the aggregate cushion feeding this development, declined from $18 billion in 2023 to $16 billion in 2024. Christopher Graham of NCCI noted at the 2025 symposium that the reserve cushion "appears to be shrinking," and that favorable prior-year development has been the principal driver of sub-90 combined ratios for the past decade.

For pricing actuaries, the implication is direct: an accident year combined ratio of 99 with a shrinking development cushion means current loss costs are barely covering current losses. Any material increase in medical severity that is not captured in the filed trend factors pushes the next cohort of accident years into deficit territory before the calendar year results signal the problem.

Medical Severity: The Trend That Changed Direction

Medical costs constitute more than half of every workers compensation claims dollar, according to W.R. Berkley CEO Rob Berkley, who described the tariff exposure at this level of share as a material uncertainty on the company's April 2025 earnings call. That 50-plus percent share means medical severity is the single highest-leverage assumption in any workers compensation loss cost filing.

NCCI's data shows medical lost-time severity increased 65% over the prior 20 years, slightly exceeding U.S. healthcare price inflation. But the trajectory was not linear. Medical severity was relatively contained through the late 2010s and decelerated sharply during the pandemic years as utilization dropped. The 2023 print of 2% looked like a continuation of the favorable trend. The 2024 print of 6% broke it.

The Workers Compensation Research Institute (WCRI) provided granular confirmation. Its 2025 Medical Price Index covering 36 states found that states without fee schedules saw median medical price growth of 40% from 2008 to 2024, while states with fee schedules held to 15% median growth over the same period. Several individual states showed sharp acceleration: Pennsylvania saw a 14% increase in medical payments per claim in 2023, tied to fee schedule updates linked to the statewide average weekly wage. Delaware logged 7% annual growth in medical payments per claim from 2021 to 2023. Wisconsin, a state without a fee schedule, ran 6% annual growth over the same window and ranked among the highest medical payments per claim among WCRI study states.

Sedgwick's workforce analytics add a demographic dimension. Workers aged 60 and older generate medical costs 35% higher than the total average, log the highest indemnity claim percentage, and average nine more temporary disability days than the workforce mean. As the insured workforce skews older, particularly in construction, healthcare, and public sector employment, the medical severity trend absorbs both price inflation and utilization intensity from an aging claim population.

The Tariff Channel: Pharmaceutical and Device Cost Inflation

The 2025 and 2026 tariff regime introduces a structural cost shock into the workers compensation medical pipeline. Section 301 tariffs on Chinese imports, maintained and expanded through 2025 and 2026, hit several product categories that flow directly into WC medical claims: syringes and needles, surgical implants, rubber medical and surgical gloves, face masks, and pharmaceutical active ingredients. The September 2024 Section 301 tariff increases raised duties on syringes and needles from 0% to 50%, certain medical devices to 25%, and rubber medical gloves from 7.5% to 25%.

Berkley's characterization that it would take 90 days to pin down the workers compensation tariff impact reflected the complexity of tracing tariff costs through the medical supply chain into claim payments. The lag is real: medical device and pharmaceutical price increases take one to two quarters to pass through at the wholesale level, then work through provider billing, fee schedule adjudication, and bill review before appearing in paid claim data. For claims filed in 2026, the tariff-driven component of medical severity will not be fully visible in the triangles until late 2027 at the earliest.

This creates a specific problem for pricing actuaries selecting the medical severity trend in a loss cost filing. The most recent paid loss data available for a 2026 filing covers accident years 2020 through 2024 and calendar year payments through early 2026. That data period contains COVID distortion (2020-2021), post-pandemic normalization (2022-2023), and only the very beginning of tariff-driven inflation (late 2025 payments). Anchoring the selected medical trend to a simple average of the most recent two to three data points understates the forward severity trajectory because the tariff effect is front-loaded in the projection period, not the experience period.

State-Level Variation: Fee Schedules as a Severity Buffer

The WCRI data reveals a stark divide in medical cost exposure between fee-schedule and non-fee-schedule states. States with active medical fee schedules held cumulative medical price growth to 15% over 16 years, while states without them absorbed 40% growth. Six non-fee-schedule states (Indiana, Iowa, Missouri, New Hampshire, New Jersey, and Wisconsin) ran prices 35% to 177% higher than fee-schedule states over that period.

The state-level loss cost filing cycle reflects this divergence. Florida, a strong fee-schedule state, approved its ninth consecutive year of WC rate cuts in late 2025, with a 6.9% average decrease effective January 1, 2026. Florida's cumulative rate reduction since the 2003 legislative reforms is approximately 85%. Pennsylvania, which ties its fee schedule to the statewide average weekly wage (creating automatic escalation), filed a 1.22% loss cost decrease effective April 2026, down sharply from the 8.67% reduction the year before.

California tells the opposite story. The WCIRB reported an accident year 2024 combined ratio of 108% of earned premium, the highest in more than 20 years. Medical benefits reached $5.2 billion, up from $4.7 billion in 2023, representing 54% of total losses. The advisory pure premium rate increased 8.7% effective September 2025. WCRI found a 5% increase in medical payments per claim in California, driven by non-hospital services and particularly physical medicine. The Functional Restoration Program added a layer of cost complexity: FRP claims averaged $127,816 in medical costs per claim versus $64,062 for comparable non-FRP claims, with attorney involvement at 94% compared to 51% in non-FRP cases.

For pricing actuaries working in NCCI states, the practical question is how much weight to give the national aggregate medical severity trend versus state-specific data. States with robust fee schedules, particularly Florida and Texas, have built-in cost containment that dampens the tariff passthrough. States without fee schedules, or states where the fee schedule is linked to wage indices that are themselves inflating, absorb the full tariff impact plus the wage-driven escalation.

The Pricing Mechanism: Selecting Medical Trend in Distorted Data

The actuarial mechanics of WC loss cost filings separate frequency and severity trending, and within severity, typically split medical and indemnity components. The medical severity trend is selected from historical paid or incurred severity data, adjusted for fee schedule changes, and projected forward through the rate effective period. This separation allows the pricing actuary to isolate the component where the forward-looking signal diverges most from historical patterns.

The challenge with the current data period is that it contains three distinct regimes: COVID suppression (2020-2021), normalization (2022-2023), and early tariff inflation (2024-2025). A standard least-squares fit through five years of medical severity data produces a trend that blends all three regimes, giving substantial weight to the suppressed and normalized periods. The result is a selected trend that is too low for the projection period if tariff-driven inflation persists or accelerates.

Several approaches address this problem. First, the pricing actuary can truncate the experience period, giving zero weight to the COVID years and fitting the trend only to 2022 forward. This produces a steeper trend but relies on fewer data points, raising credibility concerns, particularly in smaller states. Second, the actuary can apply an explicit adjustment factor for tariff-driven medical inflation, applied as a multiplicative load on the selected trend for the portion of medical costs with direct tariff exposure (devices, implants, pharmaceuticals). Third, the actuary can select the trend from the most recent data points and layer a prospective judgment call based on known tariff schedules and their expected passthrough timing.

ASOP No. 25 (Credibility Procedures) is directly relevant in smaller states where the state-specific medical severity data has limited volume. The standard requires the actuary to consider whether the subject experience is sufficient to produce a reliable trend indication on its own, or whether it should be blended with a complement of credibility drawn from a broader data set, typically the NCCI countrywide aggregate. When the countrywide medical severity trend itself is in transition, the complement of credibility carries the same directional uncertainty as the subject experience, and the actuary's documentation should note this limitation.

The indemnity side is more straightforward but still under pressure. NCCI's 6% indemnity severity increase in 2024 aligns with the BLS Employment Cost Index, which showed total compensation rising 3.4% year-over-year through Q1 2026, with the quarterly figure of 0.90% exceeding the 0.80% forecast. Benefits costs rose 1.20% in Q1 2026, the highest quarterly increase in five months. For temporary total disability (TTD) and permanent partial disability (PPD) benefits, which are directly linked to pre-injury wages, the indemnity severity trend tracks wage growth with a lag determined by the claim duration distribution. Construction and healthcare, two of the highest-frequency WC industry classes, are also among the sectors with the strongest wage growth, compounding the severity pressure where frequency is highest.

Why This Matters for Pricing Actuaries

The risk in the current environment is anchoring. Workers compensation has been profitable for so long that the institutional presumption, at carriers, at state regulators, and at NCCI itself, defaults to rate decreases. Thirty-eight states carried loss cost decreases in the most recent NCCI filing cycle, the pattern that has dominated since 2018. But the count of decrease states is now the smallest since 2018, and the magnitude of the decreases is shrinking.

Medical severity at 6%, a reserve cushion that dropped $2 billion in a single year, an accident year combined ratio at 99 while the calendar year prints 86, and a tariff regime that has not yet fully entered the paid loss data: these signals collectively argue that the loss cost trend assumptions in currently filed rates may be inadequate for accident years 2026 and 2027.

Pricing actuaries preparing state-specific WC loss cost indications should consider three concrete steps. First, run the medical trend selection with and without the COVID-era data points and document the sensitivity. Second, quantify the tariff exposure in the medical severity component using published tariff rates on medical devices and pharmaceuticals, even if the adjustment is preliminary. Third, stress-test the filed trend against the forward BLS wage growth signal for the indemnity component, particularly for state books with heavy construction and healthcare exposure.

The combined ratio will stay below 90 on a calendar year basis for at least one more year, maybe two, carried by the remaining prior-year reserve cushion. But that cushion is finite, and the accident year data already shows it. The pricing actuary who selects the medical trend from the rearview mirror rather than the windshield is the one whose filed rates will need correction first.